| 行业分析 |
|
|
|
|
| 行业分析罕见病药物市场与管理 |
| 李敏1, 吴日伟2 |
1. 武汉临空港经济技术开发区食品医药产业建设管理办公室 武汉 430043;
2. 南昌高新技术产业开发区管理委员会 南昌 330096 |
|
| Orphan Drugs Market and Management |
| LI Min1, WU Ri-wei2 |
1. Food and Pharmaceutical Industry Construction Management Office, Wuhan Airport Economic and Technological Development Zone, Wuhan 430043, China;
2. Nanchang National High-Tech Industrial Development, Nanchang 330096, China |
[1] 田圆圆, 张象麟, 董江萍. 欧美孤儿药的研究与开发现状. 中国新药杂志, 2012, 21(8): 844-850. Tian Y Y, Zhang X L, Dong J P. Current situation of orphan drug research and development in the Europe and America. Chinese Journal of New Drugs, 2012, 21(8): 844-850.
[2] Food and Drug A dministration (FDA). Rare Diseases Take Spotlight in Annual Event. .http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm244408.htm.
[3] EvaluatePharma. 2015年孤儿药研发分析报告(I). 药学进展, 2016, 40(1):62-68. EvaluatePharma. Orphan Drug Report 2015(I). Progress in Pharmaceutical Science, 2016, 40(1):62-68.
[4] Brewer G J, Mich A. Drug development for orphan diseases in the context of personalized medicine. Trans Res, 2009, 154(6): 314-322.
[5] Sharma A, Jacob A, Tandon M, et al. Orphan drug: development trends and strategies. Pharm Bioallied Sci, 2010, 2(4): 290-299.
[6] 汤立达. 2015年 FDA批准的新药. 现代药物与临床, 2016, 31(2): 265-268. Tang L D. New drugs approved by FDA in 2015. Drugs & Clinic, 2016, 31(2): 265-268.
[7] 陈玲, 刘艳红, 邹栩, 等. 2015年全球重要治疗领域新药研究的最新进展. 中国新药杂志, 2016, 25(6): 601-638. Chen L, Liu Y H, Zhou X, et al. Overview of the latest progress of global new drug research in 2015. Chinese Journal of New Drugs, 2016, 25(6): 601-638.
[8] EvaluatePharma. 2015年孤儿药研发分析报告(Ⅱ). 药学进展, 2016, 40(2):145-155. EvaluatePharma. Orphan Drug Report 2015(Ⅱ). Progress in Pharmaceutical Science, 2016, 40(2):145-155.
[9] 孙赛男, 董江萍. 国外孤儿药现状分析及对我国的启示. 中国医药工业杂志, 2015, 46(10): 1146-1150. Sun S N, Dong J P. The orphan drug status analysis of overseas and its inspirations to China. Chinese Journal of Pharmaceuticals, 2015, 46(10): 1146-1150.
[10] 谷景亮, 鲁艳芹, 钟彩霞, 等. 国外罕见病药物政策发展现状对比分析. 卫生软科学, 2013, 27(7): 393-396. Gu J L, Lu Y Q, Zhong C X, et al. Comparative analysis to rare disease pharmaceutical policy development status in foreign countries. Soft Science of Health, 2013, 27(7): 393-396.
[11] 赵赢, 刘艾林, 杜冠华. 中国与美国罕见病药物政策对比分析. 中国新药杂志, 2016,25(1):31-49. Zhao Y, Liu ’ai L, Du G H. Comparative analysis of rare disease pharmaceutical policies of China and America. Chinese Journal of New Drugs, 2016, 25(1): 31-49.
[12] 彪巍, 肖永康, 陈任, 等. 我国罕见病患者社会支持研究. 医学与社会, 2012, 25(10): 53-55. Biao W, Xiao Y K, Chen R, et al. Study on social support of rare disease sufferers in China. Medicine and Society, 2012, 25(10): 53-55.
[13] 吴方, 周迎波, 崔茉莉. 国际环境下的我国孤儿药产业发展策略研究. 中国医药工业杂志, 2015, 46(4): 428-434. Wu F, Zhou Y B, Cui M L. Research of orphan drugs industry development strategy of China under The International Environment. Chinese Journal of Pharmaceuticals, 2015, 46(4): 428-434.
[14] 陈淼, 冯文化. 国内外孤儿药研发现状. 中国新药杂志, 2014,23(7):764-768. Chen M, Feng W H. Current situation of international and national research of orphan drug. Chinese Journal of New Drugs 2014, 23(7):764-768.
[15] 韩金祥, 崔亚洲, 周小艳. 罕见疾病研究现状及展望. 罕少疾病杂志, 2011, 18(1): 1-6. Han J X, Cui Y Z, Zhou X Y. Current status and prospect of the research on rare diseases. Journal of Rare and Uncommon Diseases, 2011, 18(1): 1-6.
[16] 田苗, 田红, 解学星, 等. 罕见病用药现状分析. 现代药物与临床, 2014, 29(7): 701-707. Tian M, Tian H, Jie X X, et al. The development of orphan drugs. Drugs & Clinic, 2014, 29(7): 701-707. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
